AhR ligands in epigenetic dysregulation of T cells

AhR是一种胞质转录因子，可被多种化学物质激活，包括 环境污染物，如2，3，7，8-四氯二苯并二恶英（TCDD），导致 代谢和调节毒性作用。AhR也可被内源性配体激活 和膳食化合物。最近的突破性研究表明，AhR激活可以 还调节T细胞分化，特别是Foxp 3+调节性T细胞（T Th 17细胞在细胞外感染和自身免疫中发挥作用 多发性硬化症（MS）等疾病。有趣的是，AhR配体被证明具有 对Treg/Th 17分化的作用相反，其原因尚不清楚。为 例如，包括我们在内的研究表明，一些AhR配体，如TCDD， 促进了Th 17细胞的分化，同时抑制了Th 17细胞的分化，而色氨酸 光产物6-甲酰基吲哚并[3，2-B]咔唑（FICZ）的作用则相反。我们有 产生了令人兴奋的初步数据，表明AhR激活触发了细胞内的失调， microRNA（miR）表达和其他表观遗传途径。基于上述情况，我们将测试 AhR-配体复合物可能与二恶英反应元件相互作用假说 （DRE）对microRNA的基因启动子的作用以及诱导其他表观遗传途径， 它们共同改变miR的表达，进而调节分化， 致脑炎性T细胞我们将使用MS的实验模型来测试我们的假设 实验性自身免疫性脑脊髓炎（EAE）在Aim 1中，我们将测试TCDD是否 和FICZ在纯化的Tcl 3/Th 17细胞中诱导独特的miR表达谱。基于我们 初步数据，我们将集中在靶向FoxP 3表达的miR 31 - 5 p和miR 1192 IL-17。具体来说，我们将研究AhR-配体复合物与 这些miR基因启动子上的DRE负责不同的反应。在目标2中， 将测试TCDD和FICZ的对比效应是否是由于差异DNA 这些miR基因启动子的甲基化/羟甲基化以及由于组蛋白 修改.在目标3中，我们将确定miR模拟物或miR抑制剂以及miR抑制剂是否是miR抑制剂。 DNA甲基化/羟甲基化和组蛋白修饰的药物干预 将逆转AhR结扎后的炎症反应和临床结果， TCDD或FICZ。这项研究的意义在于，我们将发现新的 由AhR激活触发的表观遗传途径导致免疫调节。我们的研究将 还提供了新的信息，是否在体内靶向这种表观遗传途径， 预防和治疗炎症和自身免疫性疾病。

AhR is a cytosolic transcription factor that can be activated by wide range of chemicals including environmental contaminants, such as 2,3,7,8-Tetrachlorodibenzodioxin (TCDD), which leads to metabolism and regulation of toxic effects. AhR can also be activated by endogenous ligands and dietary compounds. Recent groundbreaking studies demonstrated that AhR activation can also regulate T cell differentiation, specifically the differentiation of Foxp3+ regulatory T cells (T regs) and proinflammatory Th17 cells that play a role in extracellular infections and autoimmune diseases such as multiple sclerosis (MS). Interestingly, AhR ligands were shown to have contrasting effects on Treg/Th17 differentiation, the reasons for which are not clear. For example, studies, including ours, demonstrated that some AhR ligands, such as TCDD, promoted the differentiation of Tregs while dampening that of Th17 cells, while a tryptophan photoproduct, 6-formylindolo[3,2-b]carbazole (FICZ), exerted contrasting effects. We have generated exciting preliminary data indicating that AhR activation triggers dysregulation in the microRNA (miR) expression and other epigenetic pathways. Based on the above, we will test the hypothesis that AhR-ligand complex may interact with dioxin response elements (DREs) on gene promoters of microRNAs as well as induce other epigenetic pathways, which together alter the expression of the miRs, which in turn, regulate the differentiation of encephalitogenic T cells. We will test our hypothesis using an experimental model of MS called Experimental Autoimmune Encephalomyelitis (EAE). In Aim1, we will test whether TCDD and FICZ induce unique miR expression profiles in purified Tregs/Th17 cells. Based on our preliminary data, we will focus on miR31-5p and miR1192 that target the expression of FoxP3 and IL-17. Specifically, we will examine whether the interactions of AhR-ligand complex with the DREs on these miR gene promoters are responsible for the disparate responses. In Aim 2, we will test whether the contrasting effect of TCDD and FICZ is due to differential DNA methylation/hydroxymethylation of these miR gene promoters as well as due to histone modifications. In Aim 3, we will determine whether miR mimics or antagomirs as well as pharmacological intervention of DNA methylation/hydroxymethylation and histone modification would reverse the inflammatory response and clinical outcome following ligation AhR with TCDD or FICZ. The proposed studies are highly significant in that we will identify novel epigenetic pathways triggered by AhR activation leading to immune regulation. Our studies will also provide novel information on whether targeting such epigenetic pathways in vivo can prevent and treat inflammatory and autoimmune diseases.